Actinium Pharmaceuticals to Present New Cancer Therapy Data at AACR 2026

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has announced it will present new preclinical data for its targeted radiotherapy platform at the 2026 AACR Annual Meeting. The presentation will focus on the company's ATNM-400 and Actimab-A candidates, highlighting their potential in treating various cancers. Preclinical results for ATNM-400 demonstrated broad efficacy across several solid tumor models, showcasing the versatility of the Ac-225 platform. Additionally, Actimab-A revealed a novel mechanism of action that enhances the effectiveness of standard treatments for acute myeloid leukemia (AML). These findings underscore Actinium's commitment to expanding its radiotherapy applications for both hematologic and solid malignancies. Investors are closely watching these developments as positive preclinical data often serves as a catalyst for future clinical advancements.